Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$15.11 USD

15.11
180,663

-0.26 (-1.69%)

Updated May 16, 2024 04:00 PM ET

After-Market: $15.10 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.

Henry Schein (HSIC) Expands Dental Offerings With New Pact

by Zacks Equity Research

Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.

Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy

by Zacks Equity Research

The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.

STERIS (STE) Gains on New Orders, FX Impact Dents Growth

by Zacks Equity Research

STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.

Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System

by Zacks Equity Research

Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.

Syneos Health (SYNH) to Enhance Clinical Trials With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) owing to strong international growth.

QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval

by Zacks Equity Research

QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.

IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise

by Zacks Equity Research

IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.

Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails

by Zacks Equity Research

Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope

by Zacks Equity Research

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

Thermo Fisher (TMO) Expands Global Footprint With New Facility

by Zacks Equity Research

Thermo Fisher's (TMO) new facility in China is a strategic addition to the company's global pharma services network.

Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -155.56% and 1.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The Joint Corp. (JYNT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -125% and 1.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Riya Anand headshot

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

by Riya Anand

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Wall Street Analysts Believe Orthofix (OFIX) Could Rally 47%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 46.7% upside potential for Orthofix (OFIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Orthofix (OFIX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -23.08% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.